Boosted Bacille Calmette-Guérin vaccine strategy significantly reduces tuberculosis relapse, scientists find

Дата публикации: 17-09-2026 15:40:06

Tuberculosis (TB) remains one of the world's leading causes of death, and preventing post-treatment relapse continues to be a major global health challenge. But a new study led by scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) reveals that combining an immunotherapy with the traditional Bacille Calmette-Guérin (BCG) vaccine drastically lowers the risk of TB relapse in preclinical models.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Cancer biologists bring in the B-cell reinforcements for immunotherapy	0	8.93	17-09-2026
2	Scientists overcome key barrier to self-amplifying vaccines	0	9.51	28-09-2026
3	Scientists find the gene that drives T-cell exhaustion, revealing new strategy to improve immune responses	0	9.6	23-09-2026
4	Activated donor immune cells may prevent severe complication after allogeneic stem cell transplantation	0	8.94	20-09-2026
5	Туберкулез может стать неизлечимым	0	11.3	10-09-2026
6	Teaching the immune system to control HIV	0	7.4	17-09-2026
7	Computer-designed T-cell receptors boost attacks on cancer and viral targets in early tests	0	11.68	23-09-2026
8	'Plug-and-play' CAR T technology adapts as cancer changes	0	8.18	22-09-2026
9	Newly discovered inflammatory cell signaling could open the door to autoimmune disease treatments	0	10.81	23-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 9.58. Источник: medicalxpress.com.